Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors.
A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3581.
View in:
PubMed
authors with profiles
Mark J. Ratain
Ezra Cohen